carubicin and Lung-Neoplasms

carubicin has been researched along with Lung-Neoplasms* in 11 studies

Reviews

1 review(s) available for carubicin and Lung-Neoplasms

ArticleYear
The anthracycline antineoplastic drugs.
    The New England journal of medicine, 1981, Jul-16, Volume: 305, Issue:3

    Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Daunorubicin; Doxorubicin; Female; Glycosides; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Naphthacenes; Ovarian Neoplasms; Sarcoma

1981

Trials

1 trial(s) available for carubicin and Lung-Neoplasms

ArticleYear
[Adjuvant chemotherapy with carminomycin and bleomycetin after radical surgery for squamous cell carcinoma of the lung (preliminary communication)].
    Antibiotiki, 1982, Volume: 27, Issue:3

    Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Carubicin; Clinical Trials as Topic; Daunorubicin; Humans; Leukopenia; Lung Neoplasms; Male; Methotrexate; Middle Aged; Nausea; Vomiting

1982

Other Studies

9 other study(ies) available for carubicin and Lung-Neoplasms

ArticleYear
Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
    Acta medica Okayama, 1992, Volume: 46, Issue:4

    In an attempt to predict the clinical activity of newly developed anthracycline analogues, ME2303, KRN8602, and SM5887 in the treatment of lung cancer, we compared antitumor activity of these drugs with that of adriamycin, using six human lung cancer cell lines and two drug-resistant human lung cancer sublines. Taking the pharmacokinetic data into consideration, we evaluated the relative antitumor activity: the ratio of area under the concentration-time curve of each drug to the 50% inhibitory concentration of the drug. Regarding this ratio, ME2303 was more potent than adriamycin, SM5887, and KRN8602. Cross-resistance of the new analogues to adriamycin was investigated using an adriamycin-resistant small cell lung cancer subline, SBC-3/ADM100 and an etoposide-resistant subline, SBC-3/ETP. SBC-3/ADM100 being 106-fold more resistant to adriamycin than the parent SBC-3 showed less resistance to the analogues: 1.80-fold to KRN8602, 3.80-fold to SM5887, and 8.60-fold to ME2303. SBC-3/ETP which was 52.1-fold more resistant to etoposide and 39.5-fold more resistant to adriamycin were also less resistant to the new analogues: 3.27-fold to KRN8602, 9.07-fold to SM5887, and 17.3-fold to ME2303. In conclusion, ME2303 was found to be the most potent agent among drugs tested for the treatment of lung cancer, and KRN8602 can be expected to be beneficial for the treatment of drug-resistant small cell lung cancer.

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Carubicin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Molecular Structure; Tumor Cells, Cultured

1992
[Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:7

    Phase I clinical trial of a new semi-synthetic morpholino anthracycline derivative, KRN8602, was performed. Sixteen patients with advanced malignant neoplasms refractory to standard chemotherapies received 27 courses at doses ranging from 1.5 mg/m2/day to 18 mg/m2/day by bolus injection for three consecutive days. The dose limiting toxicity was leukopenia, and a maximally tolerated dose was 18 mg/m2/day (day 1-3). The recommended dose and schedule for a phase II study is determined to be 12 mg/m2/day for three consecutive days at 3-4 weeks intervals. Among non-hematologic toxicities, nausea and vomiting were severe, but stomatitis and alopecia were rarely observed. Clinical signs of cardiotoxicity were not seen.

    Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carubicin; Drug Evaluation; Female; Hodgkin Disease; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia

1989
[Experience with and outlook for the use of cisplatin in the combined therapy of osteogenic sarcoma].
    Voprosy onkologii, 1987, Volume: 33, Issue:7

    The effectiveness of cis-diammine-dichloroplatinum (cisplatinum, platidiam, DDP) alone or as a component of combined treatment was evaluated in 85 patients with osteogenic sarcoma. The said drugs were used as adjuvants following radical surgery (group I-18 cases), in combined treatment of solitary and single lung metastases (group 2-7 cases) and in 60 patients with advanced tumors (group 3). An analysis of long-term results showed response in 30.8% in group 3. In group 2, application of chemotherapy plus surgery was followed by remissions of 2-46+-month duration (mean-13.9 months). In group I, 78.7% are expected to survive metastasis-free more than 12 months. Toxicity was moderate, with nausea and vomiting (87.1%), myelosuppression (52.8%), nephrotoxicity (48.6%) and alopecia (75.7%) being the most common side-effects.

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carubicin; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Osteosarcoma; Postoperative Care; Remission Induction; Time Factors

1987
Management of osteogenic sarcoma patients.
    Seminars in surgical oncology, 1986, Volume: 2, Issue:1

    The experience in the management of 246 patients with local osteogenic sarcoma and 67 patients with pulmonary metastases in the All-Union Oncologic Research Center, AMS USSR, is presented here. All the patients underwent surgery, but starting in 1974, various modalities of adjuvant chemotherapy (not randomized) were applied in addition. In the surgery alone group, prognosis was very poor: only 7.0% of patients survived free of disease 5 years from the primary tumor treatment. Adjuvant chemotherapy (adriamycin + vincristine + melphalan + cyclophosphamide) following amputations increased this rate to 34.0%; combining segmental resections of an affected bone with preoperative intraarterial adriamycin infusion and radiation (36 Gy) increased the rate to 35.5%. In patients with grade 4 tumor damage (tumor cells are not found upon examination of a large number of sections), the rate increased to 57.9% (P less than .05). Another regimen of adjuvant chemotherapy (platidiam or cisplatin + adriamycin + cyclophosphamide) gives a chance to 78.8% of patients to survive 1 year free of metastases. The same chemotherapy regimen enables us to achieve an objective effect in 30.8% of patients with pulmonary metastases, and its combination with surgical metastasis ablation makes it possible to obtain a complete remission, lasting from 2 to 46 months (average 13.9 months). Toxic manifestations of the chemotherapy regimens considered are moderate. Prognosis in adjuvant chemotherapy is related to age, tumor site, its local dissemination, and morphologic type of osteogenic sarcoma.

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carubicin; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Infant; Infant, Newborn; Lung Neoplasms; Male; Middle Aged; Osteosarcoma

1986
[Treatment results in osteogenic sarcoma in children and adolescents with the use of karminomycin].
    Antibiotiki, 1984, Volume: 29, Issue:1

    Carminomycin, a new antibiotic made in the USSR, was used in the treatment of 21 patients aged 5 to 15 years with extended osteogenic sarcoma. As a result of the treatment the number of the patients with lifetime prolonged for 1-2 years increased from 7.6 to 46 per cent. It was shown that the drug might be used for the prophylaxis of the localized forms of the disease in children.

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carubicin; Child; Child, Preschool; Combined Modality Therapy; Daunorubicin; Drug Evaluation; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Melphalan; Osteosarcoma; Time Factors; Vincristine

1984
[Programs for the radiation and drug treatment of metastases of Ewing's sarcoma to the lungs in children].
    Meditsinskaia radiologiia, 1983, Volume: 28, Issue:11

    As a result of total-local irradiation of the lung combined with polychemotherapy in patients with solitary metastases to the lungs, a 3-year survival in children was 52.7 +/- 12.1%, after local irradiation of the lungs and chemotherapy 30 +/- 11.8% of the patients. Combined treatment was well tolerated by pediatric patients. The results of the study have shown that radiation therapy of metastases of Ewing's sarcoma to the lungs with simultaneous polychemotherapy does not disturb external respiratory function even in a later period, the clinical manifestations of lung radiation reactions were seldom observed.

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Gamma Rays; Humans; Lung Neoplasms; Melphalan; Methotrexate; Orotic Acid; Prednisolone; Radiotherapy Dosage; Sarcoma, Ewing; Time Factors; Vincristine

1983
Modern problems of clinical chemotherapy of malignant tumours.
    Archiv fur Geschwulstforschung, 1980, Volume: 50, Issue:7

    The paper reports on a trial in which nitrosomethylurea (NMU) was compared with CCNU both in combination with vincristine and dactinomycin or the same combination with DTIC in the treatment of disseminated skin melanoma. The long-term results were statistically better in the groups with NMU than in that with CCNU while there was no statistical difference regarding the complete regression. A second trial compared NMU with CCNU in the treatment of small cell carcinoma in a regimen of combined chemo-radiotherapy. No statistical difference was to be noticed in regard to objective response and median live duration. In comparison with regimens including adriamycin the study showed an equal effectiveness of the two drugs. A third part deals with carminomycin therapy in metastatic soft tissue sarcomas and with the preventive role of postoperative 5-fluorouracil in gastric carcinoma and colo-rectal cancer.

    Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Methylnitrosourea; Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Vincristine

1980
[Antitumor activity of the components of a carminomycin complex].
    Antibiotiki, 1977, Volume: 22, Issue:1

    The antiblastomic activity of the carminomycin complex components was studied with respect to 8 strains of transplantable tumors of mice: lymphosarcoma L10-1, prestomach cancer OZh-5, sarcoma 180, lymphoid leucosis L 1210, lung bronchogenic cancer RL, lymphodenosis NK/LI, Ehrlich carcinoma and Garding-Passy melanoma. It was shown that components I, II and III possessed almost the same high antiblastomic activity and the same optimal administration schemes should be used for them. The scheme consisted of two-fold administration of the drug at intervals of 96-120 hours. Component I had broader therapeutic ranges and was more active against the lung bronchogenic cancer as compared to component II. All 3 components had no selective antiblastomic effect on the ascitic form of Ehrlich carcinoma. A comparative study of the component toxicity and pharmacology is required for final conclusion as to the recommendation of one of the components for clinical trials.

    Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Bronchogenic; Carcinoma, Ehrlich Tumor; Carubicin; Drug Evaluation, Preclinical; Lethal Dose 50; Leukemia L1210; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Experimental; Sarcoma 180; Time Factors

1977
Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Cancer treatment reports, 1976, Volume: 60, Issue:1

    Topics: Animals; Antibiotics, Antineoplastic; Carubicin; Chemical Phenomena; Chemistry; Daunorubicin; Doxorubicin; Drug Resistance; Haplorhini; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Male; Melanoma; Mice; Neoplasm Transplantation; Transplantation, Homologous

1976